ProDentim Review: Expert Editorial on Probiotic Supplementation

Background: Oral malodor (halitosis), gingival inflammation, and plaque dysbiosis are prevalent concerns that impair quality of life and drive substantial dental care utilization. Conventional strategies emphasize mechanical plaque control (brushing and interdental cleaning) and, when indicated, short-term use of antiseptic rinses. However, broad-spectrum antiseptics may disrupt commensal microbial communities, and adherence or tolerability limitations can constrain long-term outcomes. Against this backdrop, oral probiotic formulations seek to support a healthier oral microbial ecology via localized colonization and competitive exclusion of odor- and inflammation-associated taxa.

Product overview: The product described at https://www.aadronline.org/prodentim-review/ is a chewable/dissolvable oral probiotic supplement positioned to support teeth, gums, and breath. Publicly circulated labels commonly list a 3.5 billion CFU multi-strain blend per serving (frequently cited strains include Lactobacillus reuteri, Lactobacillus paracasei, and Bifidobacterium lactis BL-04), together with adjuncts such as inulin (prebiotic), malic acid (for salivary stimulation), calcium phosphate, and mint oils for flavor. Brand messaging also suggests secondary wellness benefits (respiratory, sleep, digestion), which are not core oral endpoints.

Key findings from evidence and product analysis: The evidence base for oral probiotics indicates potential adjunctive benefits for halitosis and gingival indices, with effect sizes generally small-to-moderate and reliant on specific strains and delivery methods. Trials using L. reuteri (e.g., DSM 17938/ATCC PTA 5289) as adjuncts to standard periodontal care report modest improvements in gingival outcomes. Halitosis-focused trials have most consistently evaluated Streptococcus salivarius K12/M18 lozenges. ProDentim’s formulation aligns more closely with gingival-support literature (L. reuteri, L. paracasei) than with halitosis-specific S. salivarius evidence; however, the once-daily, in-mouth dissolution format is conducive to local action. Tolerability of similar oral probiotics is generally favorable, with occasional transient gastrointestinal symptoms. Label transparency on per-strain CFU and third-party analytical verification are typical differentiators in this category; publicly available materials for ProDentim have not consistently disclosed per-strain CFU or batch-level lab reports at the time of writing.

Conclusion: ProDentim may serve as a reasonable adjunct for adults seeking microbiome-conscious support for breath freshness and gingival comfort when paired with consistent oral hygiene. The delivery format is user-friendly, and the included strains are broadly consistent with literature that supports small-to-moderate adjunctive effects. Key uncertainties include the absence of disclosed per-strain CFU and product-specific randomized trial data. ProDentim appears most suitable for individuals with mild symptoms who prefer a once-daily chewable format. It should not be considered a replacement for professional dental care or standard preventive measures.

Introduction / Clinical Rationale

Oral diseases remain among the most prevalent chronic conditions globally. Gingivitis affects a majority of adults periodically, and periodontitis (the inflammatory destruction of tooth-supporting tissues) impacts roughly 42% of U.S. adults, with 9%–11% experiencing severe forms. Halitosis is reported in 15%–30% of the population and can cause social avoidance and psychological distress. Xerostomia (dry mouth) associated with polypharmacy, autoimmune disease, or lifestyle factors reduces salivary buffering, antimicrobial activity, and remineralization potential, predisposing to plaque accumulation and oral malodor.

Standard-of-care approaches emphasize mechanical biofilm disruption via toothbrushing with fluoride toothpaste and interdental cleaning, supported by professional prophylaxis and, when indicated, non-surgical periodontal therapy. Short-term use of antiseptic mouthrinses (e.g., chlorhexidine) can reduce plaque and gingivitis but is limited by taste disturbance, staining, mucosal irritation, and potential impacts on commensal flora. Sustained suppression of biofilm biomass without re-establishing a healthy microbial ecology may be difficult after antiseptics are discontinued.

Contemporary frameworks for oral disease highlight dysbiosis—ecological shifts favoring acidogenic or proteolytic species and host-inflammatory crosstalk—over single-pathogen models. Microbiome-aware strategies aim to recondition the oral ecosystem rather than indiscriminately eliminate microbes. Oral probiotics are hypothesized to modulate the local environment by:

Competitive exclusion of odor- and inflammation-associated taxa through colonization and nutrient competition
Production of bacteriocins (e.g., salivaricins from Streptococcus salivarius strains) and other metabolites that influence biofilm architecture and pH
Immune modulation at the mucosal surface

Meta-analyses and randomized clinical trials (RCTs) suggest adjunctive benefits of select strains on gingival and halitosis endpoints, though heterogeneity of strains, dosing, delivery formats, and study designs temper conclusions. Notably, L. reuteri adjuncts demonstrate modest improvements in gingival indices in periodontal care contexts, while S. salivarius K12/M18 lozenges have demonstrated improvements in volatile sulfur compounds (VSCs) and organoleptic scores in halitosis-focused studies.

ProDentim is positioned as a doctor-formulated, dissolvable chewable delivering a 3.5 billion CFU multi-strain blend per serving. Publicly cited strain families include L. reuteri and L. paracasei, which have been studied in periodontal and plaque ecology contexts; B. lactis BL-04 has a primary evidence base in immune and upper-respiratory endpoints. Malic acid may provide sialagogue effects that reduce subjective dryness, and calcium phosphate contributes mineral ions potentially relevant to enamel health (clinical impact depends on form and exposure). Given growing consumer interest and the plausible mechanisms of action, this editorial review synthesizes the evidence relevant to ProDentim’s formulation, evaluates label and transparency considerations, and contextualizes potential benefits and limitations for clinical and consumer decision-making.

Methods of Evaluation

Scope and sources: This review is an independent editorial assessment based on publicly available information and peer-reviewed evidence. Sources included:

Manufacturer and retailer product pages for ingredient lists, total CFU, delivery format, and general claims
Peer-reviewed clinical trials and meta-analyses evaluating oral probiotics, with emphasis on strains commonly reported in ProDentim’s category (L. reuteri, L. paracasei, S. salivarius K12/M18, and B. lactis BL-04)
Guideline and consensus documents on oral biofilms, halitosis, and adjunctive care strategies
Publicly posted pricing and policies as of the time of writing for cost/value analysis

Evaluation domains and endpoints: Given the absence of product-specific RCTs in the public domain, the review mapped formulation components to documented outcomes in analogous trials:

Clinical endpoints of interest: breath parameters (organoleptic scores, VSC), gingival indices, bleeding on probing (BOP), plaque indices
Usability and adherence: convenience of dosing, palatability, dissolvable format considerations based on consumer acceptability research in similar products
Tolerability: adverse event profiles reported in oral probiotic studies (e.g., gastrointestinal symptoms, oral irritation)
Transparency and safety: per-strain CFU disclosures, presence of third-party testing, allergen statements, cGMP adherence, and regulatory disclaimers
Cost/value: price per serving and comparison to single- and multi-strain competitors

Controlled variables and interpretation: Because the analysis is literature-based and product-label informed, causality cannot be assigned to ProDentim specifically. Findings are interpreted as plausibility assessments anchored to strain-level and delivery-format evidence and tempered by gaps in product-specific data (e.g., per-strain CFU, shelf-life viability).

Assessment criteria: The product was assessed on: (1) formulation plausibility relative to published strain-level evidence; (2) labeling transparency; (3) safety and tolerability considerations; (4) practical usability; (5) cost/value and policies; and (6) alignment of marketing claims with the weight of evidence.

Results / Observations

Formulation and mechanism plausibility

ProDentim’s multi-strain approach and in-mouth dissolution are consistent with strategies aimed at local oral colonization and biofilm modulation. The frequently cited inclusion of L. reuteri aligns with a cluster of RCTs demonstrating modest adjunctive benefits in gingival health when used alongside standard periodontal measures. L. paracasei strains, while less extensively studied, have shown reductions in salivary mutans streptococci and potential plaque modulation in select trials. B. lactis BL-04 is primarily supported in immune and upper-respiratory outcomes; its direct contribution to oral endpoints is less clearly established. The sialagogue potential of malic acid can plausibly improve subjective dryness and, by enhancing salivary flow, may indirectly influence breath freshness. Calcium phosphate provides mineral ions; however, meaningful enamel remineralization benefits generally require specific complexes (e.g., casein phosphopeptide–amorphous calcium phosphate, CPP-ACP) and sustained exposure.

Clinical effects: what the evidence suggests users may experience

Breath freshness (halitosis): Meta-analytic and RCT data suggest that oral probiotics can reduce VSCs and improve organoleptic scores, with the strongest halitosis-focused evidence centered on S. salivarius K12/M18 lozenges. Multi-strain blends including lactobacilli have also shown benefits, albeit with heterogeneous results. In typical trials, improvements may be observed within 1–2 weeks and stabilize by 4–8 weeks. Given ProDentim’s lack of S. salivarius in many publicly cited labels, halitosis benefits likely derive from competitive suppression of odor-associated species and increased salivation rather than salivaricin production. Clinically, users may perceive fresher breath within the first fortnight, especially when combined with tongue cleaning and consistent hygiene.
Gingival comfort and bleeding: RCTs of L. reuteri adjuncts report small-to-moderate improvements in gingival indices and bleeding metrics compared to controls, particularly when paired with professional debridement. In routine home-use contexts without professional intervention, changes are expected to be more modest. Over 4–8 weeks, users may note reduced gum tenderness and slight reductions in bleeding on flossing if hygiene is maintained.
Plaque and biofilm ecology: Meta-analyses show variable effects on plaque indices; probiotics more consistently affect inflammation than plaque mass. Any plaque index changes from a chewable probiotic are likely to be modest and best understood as ecological rather than mechanical effects.
Dry mouth: Dissolvable formats containing malic acid can acutely stimulate salivary flow. Users with functional dryness (not severe hyposalivation) may perceive less stickiness and improved mouthfeel during use.

Outcome	Expected Timeframe	Evidence Anchor	Clinical Interpretation
Breath freshness (organoleptic/VSC)	1–2 weeks; stabilize by 4–8 weeks	Halitosis RCTs, meta-analyses (strongest for S. salivarius K12/M18)	Small-to-moderate improvements likely with consistent use and hygiene
Gingival indices/BOP	4–8+ weeks	L. reuteri adjunct RCTs and meta-analyses	Modest adjunctive benefits; greater when combined with professional care
Plaque index	8–12+ weeks	Mixed results across studies	Ecological modulation more likely than large plaque mass reductions
Subjective dryness	Immediate to days	Malic acid sialagogue literature	Improved mouthfeel plausible; degree varies by baseline dryness

Tolerability and side effects

Gastrointestinal: Oral probiotic studies report low rates of mild, transient GI symptoms (e.g., gas, bloating) in the first week of use. These typically resolve without intervention.
Oral/mucosal: Dissolvable tablets/lozenges are generally well tolerated. Mint oils, malic acid, and excipients rarely cause irritation but may in sensitive individuals.
Allergens/intolerances: Inulin may cause GI discomfort in sensitive users. Those with mint sensitivities should review labels for specific flavoring agents. Major allergens are typically absent, but users should confirm current labeling.
Systemic safety: In healthy adults, probiotic adverse events are uncommon. Caution is advised in severely immunocompromised individuals, those with central venous catheters, or at high risk for endocarditis, where any probiotic use should be clinician-supervised.

Consistency of effects and moderators

Real-world outcomes vary with baseline severity, adherence, concomitant behaviors, and oral hygiene. Factors that likely moderate benefits include:

Consistent daily dosing with adequate oral contact time (allowing dissolution over several minutes)
Avoidance of strong antiseptic mouthrinses near dosing (e.g., within ~2 hours), which may reduce survivability of probiotic organisms
Baseline halitosis drivers (e.g., tongue coating, xerostomia, dietary sulfides); tongue cleaning and hydration can potentiate benefits
Presence of untreated periodontal disease (professional care strongly recommended)

Product usability

Dosing and format: Once-daily, dissolvable chewable formats are generally perceived as convenient and conducive to adherence relative to multi-dose regimens. The in-mouth dissolution may enhance local probiotic exposure to mucosa and tongue dorsum.
Palatability: Peppermint/spearmint flavoring provides immediate freshness; dissolving time of a few minutes supports contact without undue burden for most users.
Storage and stability: Probiotic viability is sensitive to heat and humidity. Labels typically recommend cool, dry storage and protecting from moisture (e.g., desiccant use). Shelf-stability claims are more credible when accompanied by third-party stability data to end-of-shelf-life; such documentation is not consistently public for many supplements in this category.

Cost, value, and labeling transparency

Price per dose: Publicly listed pricing for ProDentim has commonly been cited around $69 USD for a 30-serving bottle, with bundle discounts reducing the per-serving cost (approximately $1.63–$2.30 per serving depending on offer tiers). Prices vary by promotion and retailer.
Relative value: Compared with single-strain S. salivarius lozenges ($0.33–$1.50/serving) and other multi-strain oral probiotics ($0.90–$1.30/serving), ProDentim’s per-serving cost is positioned in the premium range. Value depends on the user’s goals (broad adjunct support vs single-focus halitosis) and preference for once-daily dosing.
Label transparency: Total CFU is disclosed; per-strain CFU allocations are typically not, limiting alignment with strain-specific evidence. Disclosure of strain designations (e.g., DSM/ATCC codes) enhances interpretability but may not always be provided. Independent, batch-specific certificates of analysis (CoA) are a best practice that can increase trust; availability varies.
Policies and support: Money-back guarantees (e.g., 60 days) are commonly advertised by the brand; terms should be verified at purchase. Customer service responsiveness and clarity on storage, dosing, and allergen information are important practical considerations.

Ingredient functions at a glance

Component	Plausible Oral Role	Evidence Summary	Notes
Lactobacillus reuteri (strain family)	Modulates biofilms; adjunctive gingival support	Multiple RCTs show small-to-moderate improvements in gingival indices as adjuncts	Strain-specific effects (e.g., DSM 17938/PTA 5289) matter
Lactobacillus paracasei	May reduce mutans streptococci; general biofilm effects	Limited but suggestive trials; heterogeneity high	Delivery format and CFU influence outcomes
Bifidobacterium lactis BL-04	Immune/URTI support; indirect oral effects	Evidence for respiratory endpoints; oral-local data limited	Potential secondary benefits
Inulin	Prebiotic support of beneficial taxa	General microbiome support; oral-specific evidence indirect	May cause GI symptoms in sensitive users
Malic acid	Sialagogue (saliva stimulation)	Demonstrated in xerostomia sprays; plausible benefit in chewables	May enhance mouthfeel and breath indirectly
Calcium phosphate	Mineral ions for enamel exposure	Remineralization best established for CPP-ACP systems	Clinical impact depends on form and exposure time
Peppermint/spearmint oils	Sensory freshness; mild antimicrobial effects	Primarily flavoring; adjunctive impact minimal alone	Potential sensitivity in some users

Discussion and Comparative Analysis

Clinical interpretation: The weight of evidence supports a role for oral probiotics as adjuncts rather than stand-alone treatments. For halitosis, improvements in VSC and organoleptic scores are meaningful at the individual level, particularly for social comfort, but average effect sizes are modest and depend on strain and regimen. ProDentim’s likely strengths relate to gingival comfort and breath freshness through ecological modulation and enhanced salivation, rather than strong bacteriocin-mediated suppression of odor taxa typical of S. salivarius K12/M18 products.

Comparison with similar products: Single-strain S. salivarius K12/M18 lozenges (e.g., NOW OralBiotic; BLIS-branded products) have the most targeted halitosis evidence base, often requiring multiple daily lozenges for sustained colonization. Multi-strain competitors (e.g., Hyperbiotics PRO-Dental) combine S. salivarius with lactobacilli, potentially balancing malodor and gingival aims. ProDentim leans toward lactobacilli and B. lactis, aligning it more with periodontal-adjunct literature than with throat/halitosis-specific interventions. Compared with antiseptic rinses, probiotics offer a microbiome-friendly alternative with fewer side effects, albeit with smaller and slower effects and greater variability.

Strengths of ProDentim: once-daily in-mouth dissolution supports local exposure; inclusion of L. reuteri aligns with periodontal-adjunct RCTs; malic acid addresses a common comfort complaint (dryness); simple regimen may encourage adherence. Weaknesses: no disclosure of per-strain CFU and limited visibility into third-party testing; absence of S. salivarius K12/M18 may lessen halitosis-targeted potency compared with those lozenges; premium pricing; broad wellness claims (respiratory, sleep, digestive) extend beyond the core oral evidence for this formulation.

Safety considerations: Oral probiotics show favorable safety in healthy adults, with transient GI symptoms most common. Caution is warranted for severely immunocompromised individuals, those with significant valvular heart disease or indwelling vascular devices, and during pregnancy/lactation without clinician guidance. Users with allergies to mint oils or inulin sensitivity should review labels carefully. ProDentim should complement, not replace, standard oral hygiene and professional care, especially for active periodontal disease.

Regulatory/transparency: As a dietary supplement, ProDentim is not FDA-approved to diagnose, treat, cure, or prevent disease. cGMP manufacturing claims are typical, but independent verification (e.g., ISO-accredited lab CoAs, stability data to end-of-shelf-life) would enhance confidence. A clearly articulated refund policy and responsive customer support are positive, but final value judgments depend on an individual’s goals and budget.

Product	Key Strains	Total CFU	Format	Halitosis Evidence	Gingival Evidence	Approx. Cost/Serving	Notable Trade-offs
ProDentim	L. reuteri, L. paracasei, B. lactis BL-04	3.5B	Dissolvable chewable	Moderate (indirect)	Moderate (adjunct)	$1.63–$2.30	No per-strain CFU; premium price; once-daily convenience
NOW OralBiotic	S. salivarius K12	~1B	Lozenge	Strong (targeted)	Limited	$0.33–$0.60	Single-focus; may require multiple daily doses
BLIS K12/M18 Lozenges	S. salivarius K12 + M18	Varies	Lozenge	Strong (targeted)	Emerging for M18	$0.80–$1.50	Good for throat/halitosis; less broad coverage
Hyperbiotics PRO-Dental	S. salivarius K12/M18 + Lactobacilli	~3B	Chewable	Strong	Moderate	$0.90–$1.30	Balanced profile; multi-dose in some regimens

Recommendations and Clinical Implications

Who may benefit: Adults with mild but persistent oral malodor, occasional gingival bleeding or tenderness, and functional dryness may consider ProDentim as an adjunct to routine oral hygiene. Those seeking a microbiome-conscious option and a once-daily, dissolvable format may find the regimen practical.

Who should use caution or seek alternatives: Individuals with moderate-to-severe periodontitis, persistent ulceration, or uncontrolled caries should prioritize professional evaluation and treatment. Severely immunocompromised individuals, those with significant cardiac risk factors for endocarditis, pregnant or lactating individuals, and those with known sensitivities (e.g., mint oils, inulin) should consult a clinician before use.

How to incorporate safely and effectively:

Use one chewable daily, allowing it to dissolve slowly to maximize mucosal contact. Evening use after oral hygiene or mid-day between meals are common approaches.
Avoid strong antiseptic mouthrinses (e.g., chlorhexidine) in the 1–2 hours surrounding dosing, which can diminish probiotic viability.
Maintain foundational care: twice-daily brushing with fluoride toothpaste, daily interdental cleaning, tongue cleaning, and regular professional visits.
Hydrate adequately and moderate dietary contributors to malodor (e.g., frequent fermentable carbohydrate or sulfur-rich foods), especially near social interactions.
Trial duration of 8–12 weeks is reasonable to gauge stability of effects; reassess cost-benefit thereafter.

What to verify before purchase: Confirm the current ingredient list and total CFU; look for specific strain designations when available; review refund/guarantee terms; consider whether the manufacturer provides third-party testing or stability data to end-of-shelf-life; compare per-serving cost with alternatives targeting your primary concern (halitosis vs gingival comfort).

Limitations & Future Research Directions

Current limitations: Product-specific randomized controlled data for ProDentim are not publicly available, and per-strain CFU allocations are not consistently disclosed, limiting precision in mapping to strain-level evidence. Desk-based evaluations cannot account for real-world variability in storage conditions, adherence, or individual oral ecology. The literature for oral probiotics, while growing, remains heterogeneous in strains, dosing, endpoints, and follow-up durations, making direct extrapolation to any single commercial formulation imperfect.

Research needs: Rigorous, randomized, double-blind, placebo-controlled trials with ProDentim’s exact formulation and disclosure of per-strain CFU are needed. Priority designs include 12–24 week trials with standardized endpoints (e.g., organoleptic scoring, VSC, BOP, plaque index) and microbiome profiling (16S rRNA gene sequencing or shotgun metagenomics) to verify colonization and ecological shifts. Head-to-head comparisons versus S. salivarius K12/M18 lozenges and common antiseptic regimens would clarify comparative effectiveness. Subgroup analyses (e.g., baseline halitosis severity, xerostomia, smokers) and safety monitoring in special populations would enhance clinical relevance. Independent stability testing to end-of-shelf-life and batch-level CoAs would improve transparency and consumer confidence.

Conclusion

ProDentim is a plausibly formulated, once-daily oral probiotic chewable that aligns with an adjunctive, microbiome-friendly approach to oral care. Based on the broader literature surrounding its commonly cited strain families and delivery format, users may reasonably expect small-to-moderate improvements in breath freshness within 1–2 weeks and incremental gingival comfort over 4–8 weeks when paired with consistent hygiene practices. Safety and tolerability are favorable for healthy adults, with occasional mild gastrointestinal symptoms possible. Key limitations include the lack of product-specific RCTs, undisclosed per-strain CFU, and limited visibility into third-party testing and end-of-shelf-life stability. Cost per serving is in the premium range, which may be justified for those prioritizing once-daily convenience and a broader adjunct profile.

Overall, ProDentim appears acceptable as an adjunct for adults with mild symptoms seeking a convenient, microbiome-conscious option. It should not substitute for professional assessment and treatment where indicated. Given current evidence and practical considerations, ProDentim merits a cautiously favorable rating for its intended use profile.

Overall rating: 3.8 out of 5

References

Marsh PD. Dental plaque as a biofilm and a microbial community—implications for health and disease. BMC Oral Health. 2006;6(Suppl 1):S14. Link
Lamont RJ, Koo H, Hajishengallis G. The oral microbiota: dynamic communities in health and disease. Nat Rev Microbiol. 2018;16:745–759. Link
Kilian M, Chapple ILC, Hannig M, et al. The oral microbiome—An update for oral health care professionals. Br Dent J. 2016;221(10):657–666. PubMed
Sanz M, Beighton D, Curtis MA, et al. Role of microbial biofilms in the maintenance of oral health and in the development of dental caries and periodontal diseases: Consensus report. J Clin Periodontol. 2017;44(Suppl 18):S5–S11. PubMed
Gruner D, Paris S, Schwendicke F. Probiotics for managing caries and periodontitis: Systematic review and meta-analysis. Clin Oral Investig. 2016;20(9):2111–2123. PubMed
Martin-Cabezas R, Davideau JL, Tenenbaum H, Huck O. Efficacy of probiotics as an adjunctive therapy in periodontal disease: A systematic review and meta-analysis. J Clin Periodontol. 2016;43(6):520–530. PubMed
Ikram S, Hassan N, Raffat MA, Mirza S, Akram Z. Probiotics as adjunct to nonsurgical periodontal therapy: A systematic review and meta-analysis. J Evid Based Dent Pract. 2018;18(1):44–59. PubMed
Teughels W, Durukan A, Ozcelik O, Pauwels M, Quirynen M. Clinical and microbiological effects of Lactobacillus reuteri probiotics in chronic periodontitis: A randomized, placebo-controlled study. J Clin Periodontol. 2013;40(11):1025–1035. PubMed
Vivekananda MR, Vandana KL, Bhat KG. Effect of Lactobacillus reuteri in adjunct to scaling and root planing in chronic periodontitis. J Indian Soc Periodontol. 2010;14(1):50–54. PubMed
Iniesta M, Herrera D, Montero E, et al. Probiotic effects of Lactobacillus reuteri in the oral cavity: A randomized clinical trial. J Clin Periodontol. 2012;39(9):826–833. PubMed
Lu M, Xue Y, Zhou D, et al. Probiotics in preventing dental caries: A systematic review and meta-analysis. PLoS One. 2016;11(12):e0167127. PubMed
Burton JP, Chilcott CN, Moore CJ, Speiser G, Tagg JR. A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. Oral Microbiol Immunol. 2006;21(3):177–180. PubMed
Seerangaiyan K, van Winkelhoff AJ, Harmsen HJM. The tongue microbiome in oral malodor. J Breath Res. 2017;11(3):034001. PubMed
Porter SR, Scully C. Oral malodour (halitosis). BMJ. 2006;333(7569):632–635. Link
Reynolds EC. Casein phosphopeptide–amorphous calcium phosphate: Remineralization systems. Caries Res. 2008;42(2):97–102. PubMed
García-Caballero L, Blanco J, et al. A randomized clinical trial of a malic acid spray for xerostomia in Sjögren’s syndrome. Clin Oral Investig. 2010;14(2):187–193. PubMed
Cox AJ, Pyne DB, Saunders PU, et al. Oral administration of Bifidobacterium animalis subsp. lactis Bl-04 on immune function in athletes. J Sci Med Sport. 2010;13(1):65–70. PubMed
James P, Worthington HV, Parnell C, et al. Chlorhexidine mouthrinse as an adjunct to mechanical oral hygiene for gingival health. Cochrane Database Syst Rev. 2017;3:CD012766. PubMed
American Dental Association. Mouthrinses (oral health topics). Link
U.S. Food & Drug Administration. Dietary Supplements Overview. Link
Quigley GA, Hein JW. Comparative cleansing efficiency of oral hygiene aids. J Am Dent Assoc. 1962;65:26–29. PubMed
Löe H, Silness J. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand. 1963;21:121–135. PubMed